ArticleTranslational oncology2026
Single-cell sequencing reveals an immunotherapy-relevant IFITM1-marked epithelial interferon state in nasopharyngeal carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasopharyngeal carcinoma (NPC) is an immune-rich epithelial malignancy with marked malignant-cell heterogeneity and variable benefit from immune checkpoint blockade.
methodsSingle-cell RNA-seq data were integrated with inferCNV, Monocle3, DoRothEA/decoupleR, donor-aware pseudobulk differential expression and CellChat ligand-receptor modeling. External validation used NPC bulk cohorts (GSE53819, GSE12452, GSE64634 and GSE102349), TCGA-HNSC, and the anti-PD-1/PD-L1-treated HNSCC cohort GSE159067. HK1 cells were used for preliminary IFITM1 knockdown assays.
resultsAmong nine epithelial states, Epi7 emerged as a late-pseudotime interferon-responsive malignant epithelial state with marked IRF9, STAT2, IRF1 and STAT1 activity. IFITM1 was identified as its lead marker and was associated with CD274 at cell and donor levels. Donor-aware pseudobulk analysis confirmed that IFITM1-high cells carried a type I interferon and antiviral program, whereas Epi7 was enriched for chemokine signaling, antigen presentation and lymphocyte costimulation. CellChat analysis showed enhanced MIF, MHC-I, MHC-II, Midkine, APP and Galectin signaling from Epi7. Across external cohorts, IFITM1 was upregulated in NPC tumors, while the multigene Epi7 signature showed stronger correlations than IFITM1 alone across most checkpoint and immune-infiltration endpoints. IFITM1/Epi7-high tumors showed an inflamed but checkpoint-enriched microenvironment and higher composite ICB-likelihood. IFITM1 knockdown in HK1 cells reduced proliferation, colony formation and Matrigel-based invasion.
conclusionsSingle-cell sequencing identified an IFITM1-marked Epi7 epithelial interferon program, in which IFITM1 serves as a lead marker rather than an exclusive determinant, linking NPC malignant-cell heterogeneity with tumor-immune communication and immunotherapy-relevant microenvironmental remodeling. The Epi7 program may provide a translational biomarker framework for immune stratification in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.